PMC:7170415 / 11243-12572 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"172","span":{"begin":907,"end":915},"obj":"Species"},{"id":"173","span":{"begin":979,"end":986},"obj":"Species"},{"id":"174","span":{"begin":1018,"end":1025},"obj":"Species"},{"id":"175","span":{"begin":1190,"end":1198},"obj":"Species"},{"id":"176","span":{"begin":1321,"end":1328},"obj":"Species"},{"id":"177","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"178","span":{"begin":951,"end":959},"obj":"Disease"},{"id":"179","span":{"begin":1089,"end":1097},"obj":"Disease"}],"attributes":[{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:9606"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:9606"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"Tax:9606"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"Tax:9606"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"Tax:9606"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"MESH:C000657245"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"MESH:C000657245"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In response to the rapidly evolving COVID-19 pandemic, countries have used different testing approaches depending on testing capacity, public health resources, and the spread of the virus in the community. In the United States, diagnostic testing indications and capacity were limited at the beginning of the outbreak, largely because of regulatory hurdles for the use of new tests. To expand access to testing, the FDA released policies to allow laboratories to use their validated assays in a more timely manner (27). On 4 March, the Centers for Disease Control and Prevention (CDC) removed restrictive testing criteria, recommending that clinicians use their judgment to determine whether a test should be performed (28). Because testing capacity remains suboptimal (27), the implementation of this recommendation remains a challenge. The CDC still recommends priority for testing 3 groups: hospitalized patients with presentations compatible with COVID-19, other symptomatic persons at risk for poor outcomes, and persons who had close contact with someone with suspected or confirmed COVID-19 within 14 days of illness onset or have a history of travel in an affected area (28). These patients should be evaluated with a molecular diagnostic test, as described later. The CDC does not recommend testing asymptomatic persons."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T50","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"T51","span":{"begin":951,"end":959},"obj":"Disease"},{"id":"T52","span":{"begin":1089,"end":1097},"obj":"Disease"}],"attributes":[{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In response to the rapidly evolving COVID-19 pandemic, countries have used different testing approaches depending on testing capacity, public health resources, and the spread of the virus in the community. In the United States, diagnostic testing indications and capacity were limited at the beginning of the outbreak, largely because of regulatory hurdles for the use of new tests. To expand access to testing, the FDA released policies to allow laboratories to use their validated assays in a more timely manner (27). On 4 March, the Centers for Disease Control and Prevention (CDC) removed restrictive testing criteria, recommending that clinicians use their judgment to determine whether a test should be performed (28). Because testing capacity remains suboptimal (27), the implementation of this recommendation remains a challenge. The CDC still recommends priority for testing 3 groups: hospitalized patients with presentations compatible with COVID-19, other symptomatic persons at risk for poor outcomes, and persons who had close contact with someone with suspected or confirmed COVID-19 within 14 days of illness onset or have a history of travel in an affected area (28). These patients should be evaluated with a molecular diagnostic test, as described later. The CDC does not recommend testing asymptomatic persons."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T103","span":{"begin":85,"end":92},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T104","span":{"begin":117,"end":124},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T105","span":{"begin":182,"end":187},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T106","span":{"begin":239,"end":246},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T107","span":{"begin":376,"end":381},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T108","span":{"begin":403,"end":410},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T109","span":{"begin":493,"end":494},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T110","span":{"begin":515,"end":517},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T111","span":{"begin":580,"end":583},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T112","span":{"begin":605,"end":612},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T113","span":{"begin":692,"end":693},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T114","span":{"begin":694,"end":698},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T115","span":{"begin":733,"end":740},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T116","span":{"begin":770,"end":772},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T117","span":{"begin":825,"end":826},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T118","span":{"begin":842,"end":845},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T119","span":{"begin":876,"end":883},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T120","span":{"begin":1138,"end":1139},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T121","span":{"begin":1224,"end":1225},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T122","span":{"begin":1247,"end":1255},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T123","span":{"begin":1277,"end":1280},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T124","span":{"begin":1300,"end":1307},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"In response to the rapidly evolving COVID-19 pandemic, countries have used different testing approaches depending on testing capacity, public health resources, and the spread of the virus in the community. In the United States, diagnostic testing indications and capacity were limited at the beginning of the outbreak, largely because of regulatory hurdles for the use of new tests. To expand access to testing, the FDA released policies to allow laboratories to use their validated assays in a more timely manner (27). On 4 March, the Centers for Disease Control and Prevention (CDC) removed restrictive testing criteria, recommending that clinicians use their judgment to determine whether a test should be performed (28). Because testing capacity remains suboptimal (27), the implementation of this recommendation remains a challenge. The CDC still recommends priority for testing 3 groups: hospitalized patients with presentations compatible with COVID-19, other symptomatic persons at risk for poor outcomes, and persons who had close contact with someone with suspected or confirmed COVID-19 within 14 days of illness onset or have a history of travel in an affected area (28). These patients should be evaluated with a molecular diagnostic test, as described later. The CDC does not recommend testing asymptomatic persons."}

{"project":"LitCovid-sentences","denotations":[{"id":"T84","span":{"begin":0,"end":205},"obj":"Sentence"},{"id":"T85","span":{"begin":206,"end":382},"obj":"Sentence"},{"id":"T86","span":{"begin":383,"end":519},"obj":"Sentence"},{"id":"T87","span":{"begin":520,"end":724},"obj":"Sentence"},{"id":"T88","span":{"begin":725,"end":837},"obj":"Sentence"},{"id":"T89","span":{"begin":838,"end":1183},"obj":"Sentence"},{"id":"T90","span":{"begin":1184,"end":1272},"obj":"Sentence"},{"id":"T91","span":{"begin":1273,"end":1329},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In response to the rapidly evolving COVID-19 pandemic, countries have used different testing approaches depending on testing capacity, public health resources, and the spread of the virus in the community. In the United States, diagnostic testing indications and capacity were limited at the beginning of the outbreak, largely because of regulatory hurdles for the use of new tests. To expand access to testing, the FDA released policies to allow laboratories to use their validated assays in a more timely manner (27). On 4 March, the Centers for Disease Control and Prevention (CDC) removed restrictive testing criteria, recommending that clinicians use their judgment to determine whether a test should be performed (28). Because testing capacity remains suboptimal (27), the implementation of this recommendation remains a challenge. The CDC still recommends priority for testing 3 groups: hospitalized patients with presentations compatible with COVID-19, other symptomatic persons at risk for poor outcomes, and persons who had close contact with someone with suspected or confirmed COVID-19 within 14 days of illness onset or have a history of travel in an affected area (28). These patients should be evaluated with a molecular diagnostic test, as described later. The CDC does not recommend testing asymptomatic persons."}